Takeda, Protagonist Therapeutics Agree to Global Collaboration on Late-Stage Polycythemia Vera Treatment

Posted on by admin

Rusfertide is currently in a pivotal Phase III clinical trial as a potential first-in-class treatment for polycythemia vera.

Leave a Reply

Your email address will not be published. Required fields are marked *